Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Schmidt, Stefanie ^a   Kunath, Frank ^b   Coles, Bernadette ^c   Draeger, Desiree Louise ^d   Krabbe, Laura Maria ^e   Dersch, Rick ^f   Jensen, Katrin ^g   Dahm, Philipp ^h,i   Meerpohl, Joerg J ^f  

^a UroEvidence der DGU Deutsche Gesellschaft für Urologie e V   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h VA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN;

ADULT; ADVERSE EVENT; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG INSTILLATION; DRUG RESPONSE; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

EID: 85041855852     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011935     Document Type: Article

References (43)

1. Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Journal of the National Comprehensive Cancer Network : JNCCN 2013;11(4):477-84.
2. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, et al. Summary of the 8th Annual Bladder Cancer Think Tank: collaborating to move research forward. Urologic Oncology 2015;33(2):53-64.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European Urology 2013;64(4):639-53.
4. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. European Urology 2013;63(2):234-41.
5. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. Journal of Urology 2003;169(1):90-5.
6. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63(4):682-6.
7. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5a population-based study. Lancet Oncology 2014;15(1):23-34.
8. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World Journal of Urology 2011;29(4):457-63.
10. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 2013;49(6):1374-403.
11. Griffiths TRL, Action on Bladder Cancer. Current perspectives in bladder cancer management. International Journal of Clinical Practice 2013;67(5):435-48.
12. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
14. Kaplan AL, Litwin MS, Chamie K. The future of bladder cancer care in the USA. Nature Reviews. Urology 2014;11(1):59-62.
15. Kunath F, Krause SF, Wullich B, Goebell PJ, Engehausen DG, Burger M, et al. Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov. BMC Urology 2013;13:56.
16. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. Journal of Urology 2000;163(4):1124-9.
17. Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. European Urology 2011;60(1):81-93.
18. Lane PW. Meta-analysis of incidence of rare events. Statistical Methods in Medical Research 2013;22(2):117-32.
19. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, et al. Key concerns about the current state of bladder cancer. Cancer 2009;115(18):4096-103.
20. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. European Urology 2009;56(2):247-56.
21. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
22. Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. European Urology 2013;64(3):421-30.
23. Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S. The mechanism of human bladder tumor implantation in an in vitro model. Journal of Urology 1986;136(2):482-6.
24. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2015. www.R-project.org/.
25. Guido Schwarzer. meta: Meta-Analysis with R. R package version 4.1-0. Guido Schwarzer, 2015. http://CRAN.R-project.org/package=meta.
26. Rentsch CA, Birkhauser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. European Urology 2014;66(4):677-88.
27. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
28. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
29. Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. Journal of Urology 2013;190(1):50-4.
30. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD006885.pub2]
31. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU International 2010;105(3):300-8.
32. Shelley M, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. D003231. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003231]
33. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treatment Reviews 2010;36(3):195-205.
34. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a Cancer Journal for Clinicians 2013;63(1):11-30.
35. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World Journal of Urology 2009;27(3):295-300.
36. Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Annals of the Royal College of Surgeons of England 2014;96(6):415-9.
37. Sobin LH, Gospodariwicz M, Wittekind C. TNM classification of malignant tumors. 7th edition. UICC International Union Against Cancer, 2009.
38. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980;46(5):1158-63.
39. Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. European Urology 2014;66(2):253-62.
40. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. Journal of Urology 2004;171(6 Pt 1):2186-90.
41. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology 2006;49(3):466-77.
42. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
43. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;1(22):3337-51.